BioMedTracker
 
 
Resources About Us About Us

    SAMPLE DRUG PROFILE
(Data Shown as of 09/14/05)

Panitumumab  
Other Names: ABX-EGF
Est. Revenue %
Company Type U.S. Europe Japan
Abgenix, Inc. (ABGX) Lead 50% 50% 50%
Amgen, Inc. (AMGN) Partner 50% 50% 50%
Compound: Monoclonal Antibody
Target: Epidermal Growth Factor Receptor (EGFR)
Indications:  
Phase Recent Event Indication Est. Approval Date Likelihood of Approval Peak
U.S. Revenue (M)		 Upcoming Catalyst
III (Clinical Detail) 08/01/05 Colorectal Cancer 06/07 77% (10% Above Avg.) $ 284.5 Now - 09/30/05
II (Clinical Detail) 08/15/05 Renal Cell Cancer 01/11 31% (1% Above Avg.) $ 1.1 Now - 12/31/05
II (Clinical Detail) 07/27/05 Non-Small Cell Lung Cancer (NSCLC) 01/08 25% (5% Below Avg.) $ 130.0 10/30/05 - 11/03/05
Preclinical (Clinical Detail) 10/26/04 Prostate Cancer 01/10 5% (5% Above Avg.) $ 296.5
 
Drug Description
and Analysis:
 ABX-EGF is a XenoMouse-generated fully human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) with high affinity. Other drugs that impact this target are ImClone’s Erbitux (also a monoclonal antibody) and the small molecules Iressa from AstraZeneca and Tarceva from OSI, Roche, and Genentech. Iressa was the first approved EGFR inhibitor.

 
Deal Structure:
 In July 2000, Abgenix entered into a joint development and commercialization agreement with Immunex. Immunex was acquired by Amgen in 2002.

Amgen/Immunex paid Abgenix a license fee and will pay certain milestone fees. Amgen/Immunex and Abgenix will share responsibilities for phase II trials while Immunex will be responsible for phase III trials. Both Amgen/Immunex and Abgenix will have co-markeitng rights. Amgen/Immunex have been successful at designing and conducting phase III clinical trials. This co-development agreement decreases the risk that ABX-EGF's approval will be denied or delayed due to poorly designed or executed clinical trials.

 
 Questions? Email Customer Support Privacy Policy     Important Legal Disclosure 

Copyright © 2004 Sagient Research Systems, Inc.  All rights reserved.